SCHEMBL6203208

SCHEMBL6203208

O=C(Nc1ccccc1)Nc1cccc(-c2ccc(/C=C3/SC(=O)NC3=O)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.56
MAOA P21397 3/20 0.55
MAOB P27338 3/20 0.55
CISD1 Q9NZ45 2/20 0.55
PIM1 P11309 1/20 0.55
PIM3 Q86V86 1/20 0.55
PIM2 Q9P1W9 1/20 0.55
HDAC4 P56524 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
CNR1 P21554 3/20 0.53
NAT1 P18440 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 2/20 0.51
AKR1B1 P15121 1/20 0.50
GLS O94925 1/20 0.50
GLS2 Q9UI32 1/20 0.50
PIP4K2A P48426 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6203211 1.00 MGLL (0.56) MGLLMAOAMAOBCISD1PIM1
SCHEMBL6184889 0.91 MEN1 (0.55) MAOAMAOBCISD1PIM1PIM3
SCHEMBL6184894 0.91 MEN1 (0.55) MAOAMAOBCISD1PIM1PIM3
SCHEMBL6204803 0.87 MAOA (0.55) MAOAMAOBCISD1PIM1PIM3
SCHEMBL6204806 0.87 MAOA (0.55) MAOAMAOBCISD1PIM1PIM3
SCHEMBL6478008 0.86 MEN1 (0.58) MAOAMAOBCISD1PIM1PIM3
SCHEMBL6183049 0.86 HPGD (0.54) MAOAMAOBPIM1PIM3PIM2
SCHEMBL6183051 0.86 HPGD (0.54) MAOAMAOBPIM1PIM3PIM2
SCHEMBL6204139 0.82 GSK3B (0.52) MAOAMAOBCISD1PIM1PIM3
SCHEMBL6204137 0.82 GSK3B (0.52) MAOAMAOBCISD1PIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD MGLL 196/4885MAOA 719/4885MAOB 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.